IC PHARMA DISTRIBUTION: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
IC PHARMA DISTRIBUTION
Largest movements
- Receivables within one year -€128,641
down €128,641 (-79.3%), from €162,249 to €33,609
- Cash -€2,661
down €2,661 (-20.0%), from €13,288 to €10,627
mainly Other debts (-€116,486) and Trade debts (-€14,356)
- Other debts -€116,486
down €116,486 (-22.9%), from €507,991 to €391,504
- Trade debts -€14,356
down €14,356 (-99.7%), from €14,399 to €42
- Gross operating margin -€32,817
down €32,817 (-96.5%), from €34,014 to €1,198
- Other operating charges +€1,175
up €1,175 (+303.4%), from €387 to €1,563
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €175,937 | €44,635 | -€131,302 | -74.6% |
| Fixed assets | 21/28 | €400 | €400 | = | 0.0% |
| Financial fixed assets | 28 | €400 | €400 | = | 0.0% |
| Current assets | 29/58 | €175,537 | €44,235 | -€131,302 | -74.8% |
| Amounts receivable within one year | 40/41 | €162,249 | €33,609 | -€128,641 | -79.3% |
| Other amounts receivable | 41 | €162,249 | €33,609 | -€128,641 | -79.3% |
| Cash at bank and in hand | 54/58 | €13,288 | €10,627 | -€2,661 | -20.0% |
| Total equity and liabilities | 10/49 | €175,937 | €44,635 | -€131,302 | -74.6% |
| Equity | 10/15 | -€346,452 | -€346,912 | -€460 | -0.1% |
| Contributions | 10/11 | €151,400 | €151,400 | = | 0.0% |
| Reserves | 13 | €21 | €21 | = | 0.0% |
| Distributable reserves | 133 | €21 | €21 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€497,873 | -€498,333 | -€460 | -0.1% |
| Amounts payable | 17/49 | €522,389 | €391,547 | -€130,843 | -25.0% |
| Amounts payable within one year | 42/48 | €522,389 | €391,547 | -€130,843 | -25.0% |
| Trade debts | 44 | €14,399 | €42 | -€14,356 | -99.7% |
| Suppliers | 440/4 | €14,399 | €42 | -€14,356 | -99.7% |
| Other amounts payable | 47/48 | €507,991 | €391,504 | -€116,486 | -22.9% |
| Other operating charges | 640/8 | €387 | €1,563 | +€1,175 | +303.4% |
| Gross operating margin | 9900 | €34,014 | €1,198 | -€32,817 | -96.5% |
| Operating profit (loss) | 9901 | €33,627 | -€365 | -€33,992 | |
| Financial income | 75/76B | €218 | €1 | -€217 | -99.7% |
| Recurring financial income | 75 | €218 | €1 | -€217 | -99.7% |
| Financial charges | 65/66B | €303 | €95 | -€208 | -68.6% |
| Recurring financial charges | 65 | €303 | €95 | -€208 | -68.6% |
| Profit (loss) for the period before taxes | 9903 | €33,542 | -€459 | -€34,001 | |
| Income taxes | 67/77 | - | €0 | +€0 | |
| Profit (loss) for the period | 9904 | €33,542 | -€460 | -€34,002 | |
| Profit (loss) for the period to be appropriated | 9905 | €33,542 | -€460 | -€34,002 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.